Table 3.
Certainty in the estimates rated according to the GRADE. Question: Shufeng Jiedu combine antibiotic and symptomatic treatment versus antibiotic combine symptomatic treatment
| Certainty assessment | № of patients | Effect | Certainty | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| № of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | SFJD + usual care | usual care | Relative (95% CI) |
Absolute (95% CI) |
||
| Treatment failure | ||||||||||||
| 11 | randomised trials | serious a | not serious | not serious | serious b | Undetected | 35/422 (8.3%) | 79/393 (20.1%) |
RR 0.43 (0.30 to 0.62) |
115 fewer per 1,000 (from 141 fewer to 76 fewer) |
⨁⨁◯◯ LOW |
CRITICAL |
| Treatment failure - Treatment duration≤7 days | ||||||||||||
| 6 | randomised trials | serious a | not serious | not serious | serious b | Undetected | 24/192 (12.5%) | 46/193 (12.8%) |
RR 0.52 (0.33 to 0.82) |
114 fewer per 1,000 (from 160 fewer to 43 fewer) |
⨁⨁◯◯ LOW |
CRITICAL |
| Treatment failure - Treatment duration >7days | ||||||||||||
| 5 | randomised trials | serious a | not serious | not serious | serious b | Undetected | 11/230 (4.8%) | 33/200 (16.5%) |
RR 0.30 (0.16 to 0.58) |
115 fewer per 1,000 (from 139 fewer to 69 fewer) |
⨁⨁◯◯ LOW |
CRITICAL |
| Treatment failure - Mode of administration of antibiotics - iv.gtt | ||||||||||||
| 2 | randomised trials | serious a | not serious | not serious | serious b | Undetected | 10/80 (12.5%) | 20/80 (25.0%) |
RR 0.50 (0.25 to 1.00) |
125 fewer per 1,000 (from 188 fewer to 0 fewer) |
⨁⨁◯◯ LOW |
CRITICAL |
| Treatment failure - Mode of administration of antibiotics - Not reported | ||||||||||||
| 9 | randomised trials | serious a | not serious | not serious | serious b | Undetected | 25/342 (7.3%) | 59/313 (18.8%) |
RR 0.41 (0.26 to 0.62) |
111 fewer per 1,000 (from 139 fewer to 72 fewer) |
⨁⨁◯◯ LOW |
CRITICAL |
| Treatment failure - Complications - Not reported | ||||||||||||
| 11 | randomised trials | serious a | not serious | not serious | serious b | Undetected | 29/372 (7.8%) | 65/343 (19.0%) |
RR 0.43 (0.29 to 0.64) |
108 fewer per 1,000 (from 135 fewer to 68 fewer) |
⨁⨁◯◯ LOW |
CRITICAL |
| Treatment failure - Complications - AECOPD combined pulmonary infection | ||||||||||||
| 1 | randomised trials | serious a | not serious | not serious | serious b | Undetected | 6/50 (12.0%) | 14/50 (28.0%) |
RR 0.43 (0.18 to 1.03) |
160 fewer per 1,000 (from 230 fewer to 8 more) |
⨁⨁◯◯ LOW |
CRITICAL |
| Duration of hospital stay (day) | ||||||||||||
| 2 | randomised trials | serious a | not serious | not serious | serious c | Undetected | 39 | 40 | – |
MD 4.32 lower (5.89 lower to 2.75 lower) |
⨁⨁◯◯ LOW |
CRITICAL |
Notes: a The blinding was not used; b A small number of events; c Number of included patients is small. SFJD Shufeng Jiedu capsule, AECOPD acute exacerbations of chronic obstructive pulmonary disease, iv.gtt intravenous drip, CI Confidence interval, RR Risk ratio, MD Mean difference